The DOI matches its Crossref record.
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review
Abstract
BACKGROUND: Patients with thalassemia major require iron chelation therapy (ICT) to prevent complications from transfusional iron overload. Deferoxamine is effective, but requires administration as a slow continuous subcutaneous or intravenous infusion five to seven times per week. Deferiprone is a three‐times‐daily oral iron chelator, but has limited availability in the United States. Deferasirox is a once‐daily oral iron chelator that was approved in the United States in 2005 for patients older than 2 years of age with transfusional iron overload. STUDY DESIGN AND METHODS: Published evidence on rates of compliance with ICT and the association between compliance, and the incidence and costs of complications of iron overload, in patients with thalassemia major was reviewed. RESULTS: A total of 18 studies were identified reporting data on compliance with ICT, including 7 that examined deferoxamine only, 6 that examined deferiprone only, and 5 that compared deferoxamine and deferiprone; no studies reporting compliance with deferasirox were identified. In studies of deferoxamine only, estimated mean compliance ranged from 59 to 78 percent. Studies of deferiprone generally reported better compliance, ranging from 79 to 98 percent. Results of comparative studies of deferoxamine and deferiprone suggest that compliance may be better with oral therapy. Numerous studies demonstrate that that poor compliance with ICT results in increased risk of cardiac disease and endocrinopathies, as well as lower survival. Although data on the costs of noncompliance are limited, a recent model‐based study estimated the lifetime costs of inadequate compliance with deferoxamine to be $33,142. CONCLUSIONS: Inadequate compliance with ICT in thalassemia major is common and results in substantial morbidity and mortality, as well as increased costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Iron-Chelating Therapy for Transfusional Iron Overload
Brittenham, G. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmct1004810 · Cited by 366
Iron overload in thalassemia: different organs at different rates
Taher, A. T., & Saliba, A. N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.265 · Cited by 355
Synthetic and natural iron chelators: Therapeutic potential and clinical use
Hatcher, H. C., Singh, R. N., Torti, F. M., & Torti, S. V. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.121 · Cited by 242
An update on iron chelation therapy.
(2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0008-12 · Cited by 233
Metadata
- Authors
- Delea, T. E., Edelsberg, J., Sofrygin, O., Thomas, S. K., Baladi, J., Phatak, P. D., & Coates, T. D.
- Venue
- Transfusion
- Publisher
- Wiley
- Published
- 2007-09-18
- Volume
- 47
- Issue
- 10
- Pages
- 1919-1929
- ISSN
- 0041-1132 (ISSN-L)
- 1537-2995
- OpenAlex
- W2043084465
- Cited by
- 180
- References
- 0
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review. https://app.cochat.ai/papers/10.1111/j.1537-2995.2007.01416.x
- The paper
- Delea, T. E., Edelsberg, J., Sofrygin, O., Thomas, S. K., Baladi, J., Phatak, P. D., & Coates, T. D. (2007). Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review. Transfusion. https://doi.org/10.1111/j.1537-2995.2007.01416.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.